82550

Creatine kinase (CK), (CPK); total

CPT code 82550 describes a laboratory procedure used to measure the total activity of the enzyme creatine kinase (CK), also known as creatine phosphokinase (CPK), in a patient's blood. CK is a critical enzyme involved in energy metabolism, specifically the conversion of creatine to phosphocreatine, which serves as a reservoir for the rapid regeneration of adenosine triphosphate (ATP) in tissues with high energy demands. This enzyme is primarily localized within the cytosol of skeletal muscle, cardiac muscle, and brain tissue. When these cells undergo injury, necrosis, or severe stress, the cell membrane's integrity is compromised, allowing CK to leak into the extracellular space and eventually the systemic circulation. Consequently, an elevation in total CK levels serves as a sensitive, though non-specific, biomarker for tissue damage. In clinical settings, the 82550 test is frequently utilized for the early detection and ongoing monitoring of rhabdomyolysis, a potentially life-threatening condition characterized by the breakdown of skeletal muscle fibers. It is also indispensable in evaluating patients presenting with symptoms of inflammatory myopathies, such as polymyositis or dermatomyositis, and for screening individuals who may be experiencing muscle-related side effects from statin therapy. While historically used in the diagnosis of myocardial infarction, its role in modern cardiology has been largely supplanted by more cardiac-specific troponin assays; however, it remains relevant in certain diagnostic algorithms. The laboratory analysis for 82550 is typically performed on serum or plasma using automated spectrophotometric assays that measure the rate of NADPH formation, which is directly proportional to CK activity. Clinicians must interpret results in the context of the patient's muscle mass, age, and physical activity level, as strenuous exercise or intramuscular injections can lead to transient elevations. Monitoring of total CK provides valuable insight into the severity of muscle trauma and the effectiveness of therapeutic interventions designed to mitigate further muscle breakdown.

Clinical Indications

  • Suspected rhabdomyolysis due to trauma, immobilization, or extreme exertion.
  • Diagnosis and monitoring of inflammatory myopathies such as polymyositis.
  • Screening for statin-induced myopathy or myalgia.
  • Evaluation of genetic muscular dystrophies.
  • Assessment of unexplained muscle weakness or pain.
  • Investigation of dark urine (myoglobinuria) indicating muscle destruction.
  • Assessment of tissue damage following extensive surgical procedures.
  • Monitoring drug-induced muscle toxicity from medications other than statins.
  • Historical assessment of suspected acute myocardial infarction (AMI).

Procedure Steps

  1. Verify the patient's identity and review the physician's order for total creatine kinase.
  2. Explain the procedure to the patient and obtain consent for a standard blood draw.
  3. Perform a venipuncture using aseptic technique to collect a blood sample into a serum separator tube (SST) or green-top heparinized tube.
  4. Properly label the specimen and transport it to the clinical laboratory for analysis.
  5. Centrifuge the blood sample to separate the serum or plasma from the cellular components.
  6. Aliquots of the serum or plasma are placed on an automated chemistry analyzer.
  7. The analyzer utilizes an enzymatic kinetic method to measure the rate of chemical reaction, typically measuring the increase in absorbance at 340 nm as NADP is reduced to NADPH.
  8. The rate of reaction is converted into a quantitative value of enzyme activity expressed in Units per Liter (U/L).
  9. The laboratory technologist verifies the quality control and releases the final quantitative result.
  10. The clinician reviews the results to determine the clinical significance relative to established reference ranges.

Coding Guidelines

  • Use 82550 for the measurement of total creatine kinase activity.
  • If isoenzymes (CK-MB, CK-MM, CK-BB) are differentiated, see code 82552.
  • For the specific measurement of the CK-MB fraction alone, see code 82553.
  • A separate venipuncture code, such as 36415, may be reported in conjunction with 82550 depending on the setting and payer rules.
  • The test is quantitative; do not report 82550 for qualitative screenings.
  • CPT 82550 is an individual laboratory test and is not a standard component of common automated panels like the BMP (80048) or CMP (80053).
  • Ensure the medical necessity is supported by documenting muscle pain, trauma, or use of medications known to cause myopathy.

Associated ICD-10 Codes